Evaluation of prognostic factors for Peg Interferon alfa-2b plus ribavirin treatment on HCV infected patients in Pakistan

Aziz, Hafsa; Gil, M; Waheed, Yasir; Adeeb, U.; Raza, Abida; Bilal, Iram; Athar, Makshoof

doi:10.1016/j.meegid.2011.01.022

Cited by 30 publications

(29 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, RVR measured at week 4 is a strong predictor of SVR, which was achieved by 96.0% of patients ( n = 525). This outcome was consistent with other reported studies [20] and patients achieving RVR may be suitable candidates for shorter treatment durations, minimizing the economic burden.…”

Section: Discussionsupporting

confidence: 92%

Evaluation of Temporal Virological Responses to Interferon-α-2b plus Ribavirin among Genotype 3a Hepatitis C Virus-Infected Patients

Raza

Ovais²,

Aziz³

et al. 2017

Intervirology

Self Cite

View full text Add to dashboard Cite

Objectives: The present study aimed to examine the impact of rapid virological response (RVR) and early virological response (EVR) on sustained virological response (SVR) in chronic hepatitis C genotype 3a individuals. Methods: The patients were given antiviral therapy with IFN-α-2b, 3 million units 3 times a week and 800-1,200 mg of ribavirin daily adjusted to the patient's body weight (<60 kg 800 mg day−¹, and >60 kg 1,200 day−¹). The patients received this combination therapy for 24 weeks. The patients were evaluated for their viral load at week 4, 12, and 24 using RT-PCR. Results: Out of 1,471 patients, 43.3% showed a negative viral load in week 4, demonstrating RVR, whereas 56.6% maintained a high viral load. These were further separated based on viral reduction in their plasma: either negative for HCV-RNA at week 12 (n = 575), manifesting EVR, or showing a 2-log reduction in HCV viral load classified as partial EVR (PEVR; n = 259). The PEVR response was less (29.7%) compared with RVR (85.9%) and EVR (69.0%), although nonresponders were found in both groups. Conclusions: Individuals incompliant with their treatment who have a higher RVR significantly influence their SVR towards a better remission that can be treated within a short duration with standard treatment.

show abstract

Section: Discussionsupporting

confidence: 92%

Evaluation of Temporal Virological Responses to Interferon-α-2b plus Ribavirin among Genotype 3a Hepatitis C Virus-Infected Patients

Raza

Ovais²,

Aziz³

et al. 2017

Intervirology

Self Cite

View full text Add to dashboard Cite

show abstract

“…To define the predictive value of biochemical parameters we assessed the potential link between baseline ALT, GGT activity and response to antiviral treatment, and only GGT level was found to be correlated highly with SVR as an independent factor; these results are consistent with those reported by other investigators [12, 16, 27]. We did not confirm the correlation between pretreatment ALT level and sustained virological response observed by some investigators [6, 25, 27, 28].…”

Section: Discussionsupporting

confidence: 60%

Predictors of sustained virological response in patients with hepatitis C virus genotype 3 infection

Zarębska-Michaluk

Lebensztejn

Chrapek

et al. 2016

ceh

View full text Add to dashboard Cite

Aim of the studyTo assess predictors of sustained virological response (SVR) in patients with chronic hepatitis C virus (HCV) genotype 3 treated with standard therapy.Material and methodsWe retrospectively investigated data of 116 consecutive treatment-naïve patients chronically infected with HCV genotype 3, treated with pegylated interferon alpha (PegIFNα) and ribavirin (RBV) for 24 weeks. HCV RNA at week 4 (rapid virological response – RVR) and week 12 (early virological response – EVR) were measured in 85 and 105 patients respectively. Liver biopsy data were available for 103 patients. The variables were compared between patients with an SVR and those without.ResultsOverall 70.7% of patients achieved an SVR. Pretreatment factors including younger age, mild liver fibrosis as well as normal values of gamma-glutamyl transferase (GGT) and platelet count were significantly associated with higher SVR rate in univariate analysis. In the multivariate analysis only baseline platelet count > 140 000/µl and normal GGT activity were correlated with higher SVR rate. At weeks 4 and 12 HCV RNA was undetectable in 34.1% and 84.8% of patients respectively. The SVR rate was significantly higher in patients with an RVR compared to those without (p = 0.002). Only 2 patients with a rapid and early virological response did not achieve an SVR; both had negative pretreatment prognostic factors.ConclusionsIn treatment-naïve patients with genotype 3 HCV infection, low baseline platelet count and elevated GGT activity were significantly associated with poor response to PegIFNα and RBV. Achieving a rapid and early virological response was associated with higher likelihood of an SVR.

show abstract

“…RVR was a powerful predictive factor of SVR in previous studies, showing as patients with RVR had ratio of SVR meaningfully higher than others; moreover some studies suggest RVR as the most important SVR predictor. [17][18][19][20] Villela-Nogueira et al [21] identified that higher levels of GT during a pre-treatment may be a independent negative predictive factor of response to treatment: being a biochemical parameter easily available and at low cost, it may be incorporated in evaluation of response to treatment alongside with other predictive factors.…”

Section: Discussionmentioning

confidence: 99%

“…Two recent works do not detect a significant influence of genre even though both identified a meaningfully greater response in women younger than 40-50 years compared to the eldest ones Other studies consider the male gender as one of the strongest factors to predict SVR. [17,25] Furthermore data concerning rates of SVR in women are conflicting; studies which identified female gender as an independent factor linked to SVR or which noticed as not exist meaningful differences in genders were not stratified by age and considered not differences in female hormonal status; [20,22,23] other studies suggested a better response in women even after splitting the sample into age groups. [13,19,23,24] Few studies lead to identify alike responses in < 40-50 year-old patients of both genders: recent works detected not a significant influence of gender even though in presence of a better response in < 40-50 year-old women compared to the elder ones; other studies considered the male gender as a strong factors to predict SVR.…”

Section: Discussionmentioning

confidence: 99%

Can gender predict virological response to standard antiviral therapy for chronic hepatitis C? A retrospective study

Belci¹,

Collo²,

Martorana³

et al. 2016

View full text Add to dashboard Cite

Aim:The liver is a sexually dimorphic organ presenting gender differences in its metabolism, functions, enzyme activity, membrane lipid composition and immune response. This paper aimed to assess whether gender may predict virological response to standard antiviral therapy in subjects with chronic hepatitis C (CHC). Methods: The authors retrospectively analyzed 100 patients with genotype 1 CHC (55 men, 45 women), who performed standard antiviral therapy (interferon and ribavirin for 12 months) in the period 2002-2012, evaluated with blood tests and abdominal ultrasound to compare different virological and biochemical response in both gender. Results: Rate of substained virological response (SVR) was higher, but not significant, in women than men (46.7% vs. 34.5%, P = 0.05); difference became significant after stratification by age (< 50 and ≥ 50 years). Specifically in the group aged under 50 years, rate of SVR was significantly higher in women than in men (66.7% vs. 38.2%, P < 0.05). Conclusion: Female gender may predict virological response to standard antiviral therapy in subjects with CHC aged below 50 years. Considering new potent and more expensive antiviral drugs actually available for HCV treatment, it could be useful to identify candidates firstly eligible to therapy.

show abstract

Evaluation of prognostic factors for Peg Interferon alfa-2b plus ribavirin treatment on HCV infected patients in Pakistan

Cited by 30 publications

References 26 publications

Evaluation of Temporal Virological Responses to Interferon-α-2b plus Ribavirin among Genotype 3a Hepatitis C Virus-Infected Patients

Evaluation of Temporal Virological Responses to Interferon-α-2b plus Ribavirin among Genotype 3a Hepatitis C Virus-Infected Patients

Predictors of sustained virological response in patients with hepatitis C virus genotype 3 infection

Can gender predict virological response to standard antiviral therapy for chronic hepatitis C? A retrospective study

Contact Info

Product

Resources

About